Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Limited value of myeloablative therapy for late multiple myeloma.

Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R.

Blood. 1994 Jan 15;83(2):512-6.

2.

Early myeloablative therapy for multiple myeloma.

Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R.

Blood. 1994 Dec 15;84(12):4278-82.

3.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

4.

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.

Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.

Bone Marrow Transplant. 1999 Feb;23(4):317-22.

5.

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].

Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.

Srp Arh Celok Lek. 1996 Nov-Dec;124(11-12):292-6. Serbian.

PMID:
9132962
7.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

8.

Myeloablative therapy for primary resistant multiple myeloma.

Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R.

Stem Cells. 1995 Aug;13 Suppl 2:118-21.

PMID:
8520499
9.

VAD chemotherapy as remission induction for multiple myeloma.

Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, Fitzsimmons L, Ryder D.

Br J Cancer. 1995 Feb;71(2):326-30.

10.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
11.

Intensive sequential therapy for VAD-resistant multiple myeloma.

Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R.

Leuk Lymphoma. 1994 May;13(5-6):479-84.

PMID:
7915163
12.

Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

Ballestrero A, Ferrando F, Miglino M, Clavio M, Gonella R, Garuti A, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F.

Eur J Haematol. 2002 Feb;68(2):101-6.

PMID:
12038448
13.

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC.

Blood. 1998 Nov 1;92(9):3131-6.

14.

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.

Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG.

Cancer. 1996 Dec 15;78(12):2502-9.

PMID:
8952558
15.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

16.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

17.

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.

Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR.

Bone Marrow Transplant. 1999 Feb;23(3):221-6.

18.

Chemotherapy for resistant and relapsing multiple myeloma.

Alexanian R, Barlogie B, Ventura G.

Eur J Haematol Suppl. 1989;51:140-4. Review.

PMID:
2576405
19.

Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.

Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.

Haematologica. 2000 Jan;85(1):52-8.

20.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951

Supplemental Content

Support Center